How do I subscribe to ongoing alerts?

Subscribe to /feed/company/the-hiv-netherlands-australia-thailand-research-collaboration.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

The HIV Netherlands Australia Thailand Research Collaboration — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The HIV Netherlands Australia Thailand Research Collaboration pipeline: 6 marketed, 0 filed, 1 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 1 Phase 3 6 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
LPV/r + TDF/FTC or TDF/3TC	LPV/r + TDF/FTC or TDF/3TC	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase	Infectious Disease / Virology
VZV vaccination	VZV vaccination	marketed
Lopinavir/r plus saquinavir	Lopinavir/r plus saquinavir	marketed	HIV protease inhibitor combination	HIV protease	Infectious Disease / Virology
Grazaoprevir/Elbasavir/RBV	Grazaoprevir/Elbasavir/RBV	marketed	Direct-acting antiviral (DAA) combination; NS3/4A protease inhibitor + NS5A inhibitor + nucleoside analog	HCV NS3/4A protease; HCV NS5A protein; viral RNA polymerase	Virology/Hepatology
LPV/r	LPV/r	marketed	Protease inhibitor (PI) combination	HIV protease	Infectious Disease / Virology
Grazaoprevir/Elbasavir	Grazaoprevir/Elbasavir	marketed	Direct-acting antiviral (DAA) combination	HCV NS3/4A protease and NS5A protein	Virology/Hepatology
generic single tablet TAF/FTC/DTG	generic single tablet TAF/FTC/DTG	phase 3

Therapeutic area mix

Infectious Disease / Virology · 3
Virology/Hepatology · 2
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · 2 shared drug classes
ViiV Healthcare · 2 shared drug classes
Ottawa Hospital Research Institute · 2 shared drug classes
Almaza Military Fever Hospital · 1 shared drug class
Drugs for Neglected Diseases · 1 shared drug class
Egyptian Liver Hospital · 1 shared drug class
Bristol-Myers Squibb · 1 shared drug class
Federal University of São Paulo · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for The HIV Netherlands Australia Thailand Research Collaboration:

Cite this brief

Drug Landscape (2026). The HIV Netherlands Australia Thailand Research Collaboration — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/the-hiv-netherlands-australia-thailand-research-collaboration. Accessed 2026-05-17.